A Functional Germline Variant in GLI1 Implicates Hedgehog Signaling in Clinical Outcome of Stage II and III Colon Carcinoma Patients

被引:25
|
作者
Szkandera, Joanna [1 ,2 ]
Pichler, Martin [1 ]
Absenger, Gudrun [1 ,2 ]
Stotz, Michael [1 ]
Weissmueller, Melanie [1 ]
Samonigg, Hellmut [1 ]
Asslaber, Martin [3 ]
Lax, Sigurd [5 ]
Leitner, Gerhard [6 ]
Winder, Thomas [7 ]
Renner, Wilfried [4 ]
Gerger, Armin [1 ,2 ]
机构
[1] Med Univ Graz, Dept Med, Div Clin Oncol, A-8036 Graz, Austria
[2] Med Univ Graz, Div Clin Oncol, Res Unit Genet Epidemiol & Pharmacogenet, A-8036 Graz, Austria
[3] Med Univ Graz, Inst Pathol, A-8036 Graz, Austria
[4] Med Univ Graz, Clin Inst Med & Lab Diagnost, A-8036 Graz, Austria
[5] Gen Hosp Graz West, Dept Pathol, Graz, Austria
[6] Gen Hosp Leoben, Dept Pathol, Leoben, Austria
[7] Univ Zurich Hosp, Dept Med Oncol, CH-8091 Zurich, Switzerland
关键词
COLORECTAL-CANCER PATIENTS; SINGLE NUCLEOTIDE POLYMORPHISMS; FRIZZLED-RELATED PROTEIN; STEM-CELLS; GENETIC-POLYMORPHISM; TARGETING HEDGEHOG; BREAST-CANCER; TUMOR-MARKER; PATHWAY; ASSOCIATION;
D O I
10.1158/1078-0432.CCR-13-1517
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Cumulating evidence indicates that germline variants in the Wnt, Notch, and Hedgehog pathways are involved in colon carcinoma progression and metastasis. We investigated germline polymorphisms in a comprehensive panel of Wnt, Notch, and Hedgehog pathway genes to predict time to recurrence (TTR) and overall survival in patients with stage II and III colon carcinoma. Experimental Design: A total of 742 consecutively collected patients with stage II and III colon carcinoma were included in this retrospective study. Genomic DNA was analyzed for 18 germline polymorphisms in Wnt, Notch, and Hedgehog pathway genes (SFRP, DKK 2 and 3, AXIN2, APC, MYC, TCF7L2, NOTCH2, and GLI1) by TaqMan 5'-exonuclease assays. Results: In univariate analysis, the homozygous mutant variant of GLI1 rs2228226G>C was significantly associated with decreased TTR in a recessive genetic model after adjustment for multiple testing [HR = 2.35; confidence interval (95% CI), 1.48-3.74; P < 0.001] and remained significant in multivariate analysis including clinical stage, lymphovascular-, vascular-, and perineural-invasion (HR 2.43; CI 95%, 1.52-3.87; P < 0.001). In subanalyses, the association was limited to patients with surgery alone (HR = 3.21; CI 95%, 1.59-6.49; P = 0.001), in contrast with patients with adjuvant chemotherapy (HR 0.82; CI 95%, 0.35-1.95; P = 0.657). When the subgroup of patients with " high-risk" GLI1 rs2228226 C/C genotype was analyzed, no benefit of adjuvant 5-fluorouracil-based chemotherapy could be found. Conclusion: This is the first study identifying GLI1 rs2228226G>C as an independent prognostic marker in patients with stage II and III colon carcinoma. Prospective studies are warranted to validate our findings.
引用
收藏
页码:1687 / 1697
页数:11
相关论文
共 50 条
  • [31] Combining clinical factors with a genomic signature (ColoPrint) for the prognosis prediction of stage II and III colon cancer patients
    Simon, I.
    Tollenaar, R.
    Mesker, W.
    Roepman, P.
    Glas, A.
    Salazar, R.
    Capella, G.
    Moreno, V.
    van't Veer, L.
    Bernards, R.
    EJC SUPPLEMENTS, 2009, 7 (02): : 323 - 323
  • [32] The Clinical effects and prognosis of postoperative FOLFOX4 chemotherapy on patients with stage II/III colon cancer
    Qi, Hongming
    Tang, Xuhua
    Zhang, Hui
    Zhou, Hongzhi
    Lou, Shanye
    Zhu, Tieming
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (02): : 4581 - 4586
  • [33] Clinical and technical validation of a genomic classifier (ColoPrint) for predicting outcome of patients with stage II colon cancer.
    Tabernero, Josep
    Moreno, Victor
    Rosenberg, Robert
    Nitsche, Ulrich
    Bachleitner-Hofmann, Thomas
    Lanza, Giovanni
    van den Akker, Jeroen
    Roepman, Paul
    Simon, Iris
    Salazar, Ramon
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [34] Novel colon cancer tumor suppressor gene, β-defensin 1, to predict recurrence in patients with stage II and III colon cancer
    Labonte, Melissa Janae
    Bohanes, Pierre Oliver
    Yang, Dongyun
    Loupakis, Fotios
    Wilson, Peter M. D.
    Gerger, Armin
    Ning, Yan
    Wakatsuki, Takeru
    Zhang, Wu
    Benhaim, Leonor
    Ladner, Robert D.
    El-Khoueiry, Anthony B.
    El-Khoueiry, Rita
    Iqbal, Syma
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [35] Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer
    C-Y Lu
    H-L Tsai
    Y-H Uen
    H-M Hu
    C-W Chen
    T-L Cheng
    S-R Lin
    J-Y Wang
    British Journal of Cancer, 2013, 108 : 791 - 797
  • [36] Influence of KRAS mutations on clinical outcome in patients with curatively resected stage III colon cancer treated with adjuvant chemotherapy
    De Dosso, S.
    Nucifora, M.
    Sahnane, N.
    Epistolio, S.
    Riveiro, M. E.
    Bertolini, V
    Bucci, E.
    Boldorini, R.
    Fregua, S.
    Frattini, M.
    Saletti, P.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (06) : 2994 - 3003
  • [37] Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer
    Lu, C-Y
    Tsai, H-L
    Uen, Y-H
    Hu, H-M
    Chen, C-W
    Cheng, T-L
    Lin, S-R
    Wang, J-Y
    BRITISH JOURNAL OF CANCER, 2013, 108 (04) : 791 - 797
  • [38] Favorable genetic polymorphisms predictive of clinical outcome of chemoradiotherapy for stage II/III esophageal squamous cell carcinoma in Japanese
    Okuno, Tatsuya
    Tamura, Takao
    Yamamori, Motohiro
    Chayahara, Naoko
    Yamada, Toshio
    Miki, Ikuya
    Okamura, Noboru
    Kadowaki, Yuko
    Shirasaka, Daisuke
    Aoyama, Nobuo
    Nakamura, Tsutomu
    Okumura, Katsuhiko
    Azuma, Takeshi
    Kasuga, Masato
    Sakaeda, Toshiyuki
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2007, 30 (03): : 252 - 257
  • [39] Pharmacogenetic Predictors of Outcome in Patients with Stage II and III Colon Cancer Treated with Oxaliplatin and Fluoropyrimidine-Based Adjuvant Chemotherapy
    Custodio, Ana
    Moreno-Rubio, Juan
    Aparicio, Jorge
    Gallego-Plazas, Javier
    Yaya, Ricardo
    Maurel, Joan
    Rodriguez-Salas, Nuria
    Burgos, Emilio
    Ramos, David
    Calatrava, Ana
    Andrada, Encarna
    Diaz-Lopez, Esther
    Sanchez, Antonio
    Madero, Rosario
    Cejas, Paloma
    Feliu, Jaime
    MOLECULAR CANCER THERAPEUTICS, 2014, 13 (09) : 2226 - 2237
  • [40] Clinical characteristics and outcome of patients with stage III esophageal carcinoma: a single-center experience from Turkey
    Ugur, Vahide I.
    Kara, Sakire P.
    Kucukplakci, Bulent
    Demirkasimoglu, Taciser
    Misirlioglu, Cem
    Ozgen, Aytul
    Elgin, Yesim
    Sanri, Ergun
    Altundag, Kadri
    Ozdamar, Nadi
    MEDICAL ONCOLOGY, 2008, 25 (01) : 63 - 68